Amphastar Pharmaceuticals, Inc.
AMPH
$29.06
$0.2450.85%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.16% | 19.01% | 19.16% | 17.78% | 18.89% |
| Total Other Revenue | -62.56% | 46.56% | -- | -- | -- |
| Total Revenue | 13.59% | 20.33% | 31.80% | 30.38% | 29.14% |
| Cost of Revenue | 23.24% | 24.86% | 23.35% | 23.99% | 16.17% |
| Gross Profit | 5.66% | 16.57% | 39.74% | 36.28% | 42.18% |
| SG&A Expenses | 17.57% | 24.28% | 21.65% | 22.62% | 20.72% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.40% | 21.91% | 18.73% | 17.15% | 13.59% |
| Operating Income | 2.87% | 16.74% | 71.44% | 73.39% | 85.76% |
| Income Before Tax | 11.70% | 9.62% | 56.39% | 54.12% | 47.46% |
| Income Tax Expenses | -6.79% | -17.72% | 30.14% | 11.68% | 35.59% |
| Earnings from Continuing Operations | 15.98% | 16.58% | 63.34% | 66.04% | 50.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.98% | 16.58% | 63.34% | 66.04% | 50.51% |
| EBIT | 2.87% | 16.74% | 71.44% | 73.39% | 85.76% |
| EBITDA | 8.69% | 23.91% | 76.42% | 73.84% | 79.73% |
| EPS Basic | 15.72% | 16.54% | 62.96% | 66.32% | 50.98% |
| Normalized Basic EPS | 9.67% | 7.81% | 52.75% | 44.59% | 50.43% |
| EPS Diluted | 18.13% | 17.86% | 61.53% | 62.57% | 47.67% |
| Normalized Diluted EPS | 12.21% | 8.67% | 51.04% | 41.54% | 47.57% |
| Average Basic Shares Outstanding | 0.34% | 0.15% | 0.09% | -0.41% | -0.59% |
| Average Diluted Shares Outstanding | -1.78% | -0.37% | 1.15% | 1.60% | 1.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
